Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO4987655 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO4987655 | DRUG | Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2) |
Inclusion Criteria: * adult patients, \>=18 years of age; * advanced and/or metastatic cancer not amenable to standard therapy; * any solid tumor type (Part 1); malignant melanoma or other responsive tumor type (Part 2); * measurable and/or evaluable disease (Part 1); \>=1 measurable lesion (Part 2...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
RO4987655 is an investigational small molecule developed by Roche Holding AG for the treatment of advanced solid tumors, including neoplasms. It is an oral agent that has been studied in a Phase 1 dose-escalation trial in patients with advanced solid tumors. It is not an approved therapy.
RO4987655 targets MAP2K1 and MAP2K2, also known as MEK1 and MEK2. It is a small molecule inhibitor of these kinases, which sit in the MAPK signaling pathway that drives cell proliferation in many solid tumors. Inhibiting MAP2K1 and MAP2K2 is intended to block that signaling.
RO4987655 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche sponsored the clinical program for the compound, including the Phase 1 dose-escalation study in patients with advanced solid tumors.
RO4987655 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. Only one clinical trial has been conducted, and that trial is now completed.
RO4987655 was studied in one clinical trial, NCT00817518, titled A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors. That Phase 1 trial enrolled 145 patients across France, Germany, the Netherlands, Spain, and the United Kingdom, and it is completed.
RO4987655 was studied for the treatment of advanced solid tumors, or neoplasms. The Phase 1 trial NCT00817518 evaluated dose escalation in adults aged 18 years and older with advanced solid tumors. The study is completed, and RO4987655 remains an investigational agent rather than an approved treatment.